Cardiotoxicity associated with sunitinib.

摘要

Pfizer is committed to making important safety information about sunitinib malate available to physicians and patients.Tammy Chu and colleagues' retrospective subanalysis of 75 patients from a previously reported phase l/ll trial in gastrointestinal stromal tumour (GIST)1 provides valuable information for the management of patients taking sunitinib who have limited treatment options. The findings underscore the importance of a collaborative team of health-care professionals working together